Barclays PLC Acquires 59,395 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Barclays PLC lifted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 29.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 263,657 shares of the company's stock after purchasing an additional 59,395 shares during the quarter. Barclays PLC owned 0.13% of Cellebrite DI worth $4,439,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of CLBT. Quarry LP acquired a new stake in Cellebrite DI in the third quarter worth approximately $27,000. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Cellebrite DI by 59.6% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company's stock worth $33,000 after purchasing an additional 1,017 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock valued at $52,000 after purchasing an additional 1,742 shares during the last quarter. Pathway Financial Advisers LLC boosted its holdings in Cellebrite DI by 1,583.8% during the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock worth $74,000 after buying an additional 4,118 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new position in Cellebrite DI in the second quarter worth approximately $71,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CLBT has been the subject of a number of analyst reports. Needham & Company LLC upped their price objective on shares of Cellebrite DI from $17.00 to $21.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. TD Cowen lifted their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Monday, December 16th. Finally, Craig Hallum raised their target price on Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI currently has a consensus rating of "Buy" and a consensus target price of $20.57.

Cellebrite DI Price Performance

Shares of CLBT stock traded up $1.23 during trading on Friday, reaching $22.52. The company had a trading volume of 1,979,821 shares, compared to its average volume of 1,187,580. The firm's 50 day simple moving average is $19.23 and its two-hundred day simple moving average is $16.18. Cellebrite DI Ltd. has a one year low of $7.91 and a one year high of $22.63. The company has a market capitalization of $4.64 billion, a PE ratio of -14.53, a PEG ratio of 2.71 and a beta of 1.51.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The firm had revenue of $106.90 million for the quarter, compared to the consensus estimate of $102.06 million. During the same quarter last year, the firm posted $0.09 EPS. The business's quarterly revenue was up 27.0% on a year-over-year basis. Analysts forecast that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.